Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer.
Most cases of HCC are as a result of either a viral hepatitis infection (hepatitis B or C), metabolic toxins such as alcohol or aflatoxin), conditions like hemochromatosis and alpha 1-antitrypsin deficiency or NASH.
Treatment options for HCC and prognosis are dependent on many factors but especially on tumour size, staging, and extent of liver injury. Tumour grade is also important; high-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs.
HCC is relatively uncommon in the United States and many other developed countries. It occurs most commonly in countries were hepatitis B infections are common.
We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.
Bentham science publishers. "towards the goal of precision therapy in hepatocellular carcinoma: hepatocellular carcinoma is a highly lethal disease, therefore effective and tolerable treatment is urgently needed." sciencedaily. Sciencedaily, 7 march 2016. Www.sciencedaily.com/releases/2016/03/160307152830.htm .
Shimizu m, shirakami y, imai k, takai k, moriwaki h. Acyclic retinoid in chemoprevention of hepatocellular carcinoma: targeting phosphorylated retinoid x receptor-a for prevention of liver carcinogenesis. J carcinog [serial online] 2012 [cited 2016 jun 14];11:11. Available from: http://www.carcinogenesis.com/text.asp?2012/11/1/11/100398